Moss A A, Lin S K, Riegelman S
Invest Radiol. 1980 Nov-Dec;15(6 Suppl):S132-5. doi: 10.1097/00004424-198011001-00028.
The pharmacokinetics, biliary excretion, plasma protein binding, enterohepatic circulation, and biotransformation of iopanoic acid and iodoxamic acid in the rhesus monkey were evaluated by a dynamic infusion method. The dynamic method has the advantage that the pharmacokinetic parameters involved in the hepatic uptake and biliary excretion can be evaluated from a single infusion experiment. The percentage of iodoxamic acid not bound to plasma protein varied from 6.1-41.2% as iodoxamic acid plasma levels were from 42 microM to 912 microM. Using the Freundlich isotherm approach, more than one class of binding site for iodoxamic acid was found. A saturable biliary excretion mechanism or hepatic uptake mechanism was determined with a Vmax of 1.03 microM/kg/min. Less than 1% of iodoxamic acid injected into the duodenum was recovered in the bile in 12 hours. Iodoxamic acid was found to exist in blood as an unchanged species. Iopanoic acid was extremely highly bound to monkey plasma protein. As blood concentration increased from 18.9 to 464 microM, the percentage unbound in plasma protein varied from 0.1-2.8%. Biliary excretion rates of iopanoic acid were fitted by a computer to the Michaelis-Menten equation against unbound plasma concentration and the average Vmax value was found to be 0.85 microM/kg/min with an average Kmax value of 0.253. Iopanoic acid was found to exist in monkey blood as unchanged species and in the bile mainly as an ester glucuronide. Coadministration experiments revealed that the interaction of iodoxamic acid and iopanoic acid in the monkey is complex. The compounds appear to compete for plasma protein binding sites as well as for binding sites on intrahepatic protein. The biliary excretion data seem to fit the ligant exclusion model, in which iopanoic acid acts as an inhibitor and competes with iodoxamic acid for binding to either of two identical sites in the liver, which, presumably, is the rate-limiting step in the liver's overall elimination of these radiographic agents.
采用动态输注法评估了恒河猴体内碘番酸和碘多啥酸的药代动力学、胆汁排泄、血浆蛋白结合、肠肝循环及生物转化。动态法的优势在于,可通过单次输注实验评估肝脏摄取和胆汁排泄过程中涉及的药代动力学参数。当碘多啥酸血浆浓度在42微摩尔/升至912微摩尔/升之间时,未与血浆蛋白结合的碘多啥酸百分比在6.1%至41.2%之间变化。采用弗罗因德利希等温线方法,发现碘多啥酸存在不止一类结合位点。确定了一种可饱和的胆汁排泄机制或肝脏摄取机制,其Vmax为1.03微摩尔/千克/分钟。注入十二指肠的碘多啥酸在12小时内胆汁回收量不到1%。发现碘多啥酸在血液中以原形存在。碘番酸与猴血浆蛋白的结合程度极高。随着血药浓度从18.9微摩尔/升增加到464微摩尔/升,血浆蛋白中未结合的百分比从0.1%变化至2.8%。通过计算机将碘番酸的胆汁排泄速率与游离血浆浓度拟合到米氏方程,发现平均Vmax值为0.85微摩尔/千克/分钟,平均Kmax值为0.253。发现碘番酸在猴血液中以原形存在,在胆汁中主要以酯葡萄糖醛酸苷形式存在。联合给药实验表明,碘多啥酸和碘番酸在猴体内的相互作用较为复杂。这两种化合物似乎会竞争血浆蛋白结合位点以及肝内蛋白上的结合位点。胆汁排泄数据似乎符合配体排斥模型,即碘番酸作为抑制剂,与碘多啥酸竞争结合肝脏中两个相同位点中的任何一个,这可能是肝脏整体消除这些造影剂过程中的限速步骤。